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Enteral stents: Complications and their management
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A  B  S  T  R  A  C  T
The treatment of malignant colonic and gastric outlet obstruction with self-expanding metallic stents (SEMS) is an established technique that can be 
performed by radiologic or a combination of radiologic and endoscopic guidance. The procedure is very effective to relieve the obstructive symptoms 
of advanced malignancies, with important clinical benefits and significant improvement in quality of life for the patients. Despite much advance-
ment in the designs of SEMS, enteral stent placement is still associated with some significant early and late complications. Stent dysfunction mainly 
caused by tumor ingrowth/over growth, and stent migration when covered stent are used, are relatively common complications and many times re-
quire reinterventions.
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Introduction
The clinical use of enteral self-expanding metallic stents 
(SEMS) has evolved over the years, when initially introduced, 
SEMS were used primarily for relieving obstructive symptoms 
in terminal cancer patients, clinical applications have now ex-
panded to include patients with benign stenosis and other benign 
conditions such as post operative leaks. The initial enthusiasm 
for enteral stenting has been somewhat dampened by the myriad 
of complications, many requiring reinterventions. Long-term 
complications have been relatively common and the utility of 
SEMS in the palliation of certain gastrointestinal malignancies 
compared with the traditional surgical methods has been recently 
questioned. Twenty years of experience with SEMS has taught us 
many important lessons in a field that is still evolving, while the 
search for the ideal SEMS continues. The purpose of this chapter 
is to review the early and late complications of enteral (colonic 
and gastroduodenal [GD]) SEMS and their management. 
Complications after Colonic Stent Implantation 
Colorectal cancer (CC) is the third most common malignancy 
and the third leading cause of cancer death in the civilized world.1 
The prognosis of CC has improved due to advances in diagnosis 
and therapy. CC occasionally presents with urgent symptoms, 
such as rectal bleeding, perforation and obstruction. Colorectal 
acute malignant obstruction occurs between 8% and 29% of 
patients with CC, and this situation requires urgent treatment be-
cause of the possibility of serious complications, such as perfora-
tion, colonic necrosis and septic shock complications.2 
Acute malignant colorectal obstruction causes high morbid-
ity and mortality,3–5 and is a poor prognostic factor.6–8 Emergency 
surgical decompression is the gold standard for the treatment of 
acute malignant bowel obstruction. In these circumstances, the 
mortality and morbidity of emergency surgery are higher than 
for elective surgery.8,9 Approximately 50% of patients undergoing 
this surgery end up with a permanent stoma, which worsens the 
quality of life of patients.10
Currently an effective, safe and feasible alternative for these 
patients with malignant colorectal obstruction is decompression 
by SEMS.11–14 The normalization of intestinal transit by stenting 
via fluoroscopic or endoscopic facilitates elective surgery, de-
creases surgical time and avoids temporary or permanent stoma. 
Both endoscopic and fluoroscopic techniques for SEMS place-
ment have their advantages and disadvantages. Technical results 
are similar between the two techniques in the majority of series.15 
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Endoscopic guidance is very useful for proximal lesions and when 
very tortuous anatomy is present. In recent years dedicated colon-
ic stents have been available with more flexible stents and longer 
delivery systems that have resulted in lesser incidence of device 
related complications; despite these recent advances, the overall 
re-intervention rate is still high and the ideal colorectal stent is 
yet to be developed.16 Complications after colorectal stent place-
ment are usually minor but severe life-threatening complications 
can develop any time after the procedure.17
Frequency and Types of Complications
Complications are divided in early (< 30 days) and late (> 30 
days) complications. Complications are also classified as minor 
complications, when they are self-limited and do not require ad-
ditional interventions, while major complications are those that 
require additional interventions, hospital admission or lead to pa-
tient’s death. 
Perforation is the main early complication in all published 
series regardless of radiologic guidance, endoscopic guidance, or 
a combination of the two (range, 0%–13%). Minor complications 
related to colon stent placement such as mild to moderate rectal 
bleeding, transient anorectal pain, temporary incontinence, and 
fecal impaction are common in many reports (Table 1).16–26
Late complications related to SEMS mainly include re-ob-
struction and migration of the stent, and rarely perforation. Mi-
gration incidence varies from 4% to 26% and is one of the more 
frequent complications observed at early follow-up.20–26 Obstruc-
tion can recur as a result of fecal impaction or tumor ingrowth.21 
Growth of the tumor through the mesh is the main disadvantage 
of uncovered stents, and its incidence varies from 2% to 20%.19,20 
The use of covered stents could prevent this complication, but 
with the potential inconvenience of a higher rate of migration. 
Although some complications are unavoidable, certain factors 
Table 1 Main Complications after Colonic Stent Placement
Complication Incidence (%)
Early complications
    Major
        Death 0–15.0
        Perforation 0–12.8
        Migration 0–4.9
        Re-obstruction 0–4.9
        Bleeding 0–3.7
    Minor
        Stent failure 0–11.7
        Pain 0–7.4
        Tenesmus 0–22.0
        Fever -
Late complications
    Major
        Re-obstruction 4–22.9
        Migration 1–12.5
        Perforation 0–4.0
    Minor
        Incontinence -
        Fistula -
Data based on the European Society of Gastrointestinal Endoscopy (ESGE) 
Clinical Guideline of the article of van Hooft et al (Endoscopy. 2014;46:990-
1053).20
Table 2 Some Factors Associated with Colonic Complications after Stent Placement
Factor Details 
Operator experience Excessive manipulation can be associated with perforation, most of the time caused by the guidewires trying to cross the obstruction.
Inadequate centering of the stent in the lesion can result in early stent migration. Placing a stent that is too short with inadequate covering 
of the tumor margins can be associated with lack of resolution of the obstructing symptoms.
Complications are more common when the procedure is performed by less experienced operators.15
Balloon dilatation Many authors consider pre- or post-procedure balloon dilation of colonic stenosis an absolute contraindication.13,14
A high incidence of perforations (10%) associated with balloon dilation was reported in review with 568 patients.21 
Stent type Certain stents maybe too rigid for the normal curvatures of the colon. A study demonstrated that the use of the Wallstent was associated 
with higher incidence of technical difficulties such as insufficient stent expansion and stent misplacement; and higher incidence of major 
complications such as perforation, stent occlusion, migration, stent erosion/ulcer and stent collapse than other stents.25 
Perforation can also be associated with the delivery system of the stent, it has been reported a high incidence of perforation with the use of 
dual colorectal stent due to the rigidity of the delivery system.15
Covered stents have been used to prevent reocclusion of the stent by tumor ingrowth but are associated with a much higher incidence of 
stent migration.
Type of stricture Higher incidence of stent migration, perforation, need for surgery and procedure related mortality has been reported in patients with extrin-
sic compression of the rectosigmoid area. However, other studies, reported similar rate of complications than patients with intrinsic lesions.
Longer strictures (> 10 cm) also had worse outcomes than shorter strictures; possibly due to longer strictures tend to involve the curvatures 
of the colon.
Angulated lesions have higher rate of stent migration and perforations, these types of lesions are usually seen in the rectosigmoid area.
Some series report a higher incidence of overall complications when the obstruction is complete, this could be related to microperforations 
caused by the obstruction and/or technical difficulties when crossing the lesions with higher manipulations. Others reported higher clinical 
failures in case of complete obstructions.15
Chemoradiation use The use of chemoradiation before and after colonic stents has been associated with a higher incidence of perforation and stent migration. 
Migration can be explained by improvement in the stenosis with tumor shrinkage after chemoradiation. In many of these patients there is 
no recurrence of the obstruction after stent migration and additional interventions may not be required.14
The recent use of bevacizumab, an antiangiogenic agent in combination with other chemotherapy drugs have resulted in higher bowel per-
foration rates compared with controls in the absence of colonic stent placement. Perforations are more common and also appear to occur 
earlier in patients with palliative colonic stents taking bevacizumab.26
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can be associated with a higher incidence of major complications 
(Table 2).13-15,21,25,26
Minor Complications 
In general minor complications only require clinical observa-
tion and most resolve without reinterventions. 
Stent failure
Due to the rigidity of the tumor or by being located in a very 
acute angle, after proper release, the stent does not open enough to 
restore intestinal transit. In these cases, it is recommended to im-
plant a second coaxial stent to provide more radial strength (Fig. 1).
Pain and tenesmus 
Pain is one of the most common complains after stent place-
ment. It is usually self-limited and tends to improve over time. If 
post-stenting pain becomes severe, care should be taken to rule 
out serious complications such as perforation and/or stent migra-
tion. Migration of stents into the anorectal area is also a potential 
source of significant pain that does not respond to analgesics. In 
a retrospective study by Song et al,27 stents placed less than 7 cm 
from the anus caused significant pain and tenesmus that may re-
quire lifelong analgesics or removal of the stent. Retrievable stents 
seem to be a good choice for patients with low rectal obstruc-
tions, since pain, incontinence, or tenesmus are potential severe 
problems that could be not relieved unless the stents are removed. 
Currently several retrievable colonic stents are available in Europe 
and Asia. 
Bleeding 
The most common complication in this category, bleeding is 
usually related to the pressure of the stent against friable tumor. 
In the majority of the cases the hematochezia is resolved with 
conservative treatment. Blood transfusion and surgical interven-
tion are rarely required. Late bleeding can be related to erosion/ 
ulcers of the colonic mucosa by the stents. Occasionally radiation 
colitis may cause bleeding after stent placement.
Fecal impaction
Fecal impaction usually presents as sudden onset of bowel 
obstruction. Diet counseling with a high fiber diet and routine use 
of laxatives are measures that may help prevent impaction. Once 
impaction is suspected, cleaning enemas are performed. Impaction 
may require the radiologist to perform a water soluble enema to 
diagnose the obstruction followed by flushing of the colon with 
saline. Endoscopic lavage is also frequently performed. In some 
cases lavage is not sufficient and mechanical recanalization under 
fluoroscopic or endoscopic guidance may be required to relieve 
the blockage. When intervention is required to relieve the impac-
tion, this complication is classified as a major complication.
Incontinence 
This could be a very disabling complication that usually oc-
curs after placement of low rectal stents that may interfere with 
the anal sphincter function. This complication may require re-
moval of the stent. Patients with tumors located near the rectum 
need to be counseled about this possible problem before the pro-
cedure is performed.
Bacteremia and fever
This is an infrequently reported complication; transient bacte-
remia produced by enteric bacteria has been reported. In spite of 
this possibility routine antibiotic prophylaxis is usually not rec-
ommended.14 
Major Complications 
The three most important major complications due to their 
clinical implications are perforation, migration and reobstruction. 
Perforation 
Perforation is the most serious complication after colorectal 
stent placement and the leading cause of death related to the 
procedure. Many patients with malignant colonic obstruction 
have advanced disease and are in a poor medical condition. These 
patients may not tolerate an exploratory laparotomy and may die 
soon after the perforation with or without surgery.14 Perforation 
A B
Fig. 1. (A) Barium enema shows incomplete ex-
pansion of a Wallstent placed in the rectosigmoid 
area (arrow). Note the severe curvature of the co-
lon distal to the stent. (B) Radiograph shows bet-
ter stent expansion after placement of a coaxial 
stent (arrows). 
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should be suspected when patients develop symptoms of peritoni-
tis (severe pain, fever, leukocytosis) or when free gas is detected at 
erect radiography after stent placement (Fig. 2). Minimal amounts 
of free intraabdominal gas are better detected with computed 
tomography (CT). Perforation can be confirmed as extraluminal 
contrast leakage on water soluble contrast enemas (Fig. 3). Perfo-
ration usually occurs in the first 3 days after stent placement. In 
a systematic review of 58 publications (598 cases) of stent place-
ment for the treatment of colorectal obstruction, the perforation 
rate was 4%.21 Other reported perforation rates range from 7% 
to 10%.14 It is often difficult to know if these perforations were 
iatrogenically caused, preexistent, or worsened by manipulation. 
The greatest risk of perforation is in the rectosigmoid area. Per-
foration is usually an acute complication and procedure related. 
Excessive manipulation with the guidewire, more commonly in 
higher degrees of obstructions and procedures performed by in-
experienced operators, are potential causes of acute perforation 
(Fig. 3). Balloon dilation before stent placement has been associ-
ated with a higher incidence of perforation and its routine use is 
not recommended. Perforation can also be related to unsuccess-
ful bowel decompression after the procedure.24 Late perforation 
is related to stent pressure into the tumoral area and it is usually 
stent related. Perforations are also caused by the relatively rigid 
stents in the normally curved areas of the colon, or when the 
stents are placed in eccentric positions. The ends of the stents can 
traumatize the normal colonic mucosa during peristalsis or in the 
case of flared colorectal stents, cause perforations from pressure 
necrosis at the ends of the stents.27 Perforation can also be related 
to stent migration with unresolved or recurrent bowel obstruc-
tion.15,17 Perforations are almost always managed by emergency 
surgical exploration (65%). In some cases, limited perforations 
can be managed with bowel rest and broad spectrum antibiotics. 
Some limited perforations may present as localized abscesses and 
percutaneous drainage combined with prolonged broad spectrum 
antibiotic therapy has been successful in most cases, avoiding a 
major surgery in these terminal patients. A higher incidence of 
perforations is seen in patients receiving chemotherapy, especially 
in patients on bevacizumab.26 As the overall long-term survival 
of patients with colon cancer improves with newer chemotherapy 
regimens improves, the incidence of stent-related complications is 
likely to increase.
A B C
Fig. 2. (A) Plain radiograph shows large pneumoperitoneum (arrows) in a patient that complained of severe abdominal pain and peritonitis two days after colonic 
stent placement. (B) Radiograph shows the stent in the transverse colon (arrow). (C) Photograph of the surgical specimen shows the stent with the site of perforation 
(arrow). 
A B
Fig. 3. (A) Radiograph shows extravasation of 
contrast (arrows) after difficult manipulation 
of the obstruction. (B) Radiograph shows the 
deployed stent (arrow). The patient remained 
without symptoms or sings of perforation and 
underwent elective surgery 11 days later. 
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Migration
Migration rates associated with uncovered stents have ranged 
from 3% to 12%. The overall migration rates for covered stents 
are reported to be as high as 30% to 50%.21 Prosthesis migration 
does not directly depend on the technique used for placement, 
but rather on the stent type and on the degree and location of the 
stenosis, because it is caused by a lack of fixation of the metal-
lic mesh to the tumoral tissue.14 The narrower the stenosis, the 
less the possibility of prosthesis migration. Migration rates are 
higher in the distal third of the descendent colon and sigmoid 
colon because of the greater mobility of these segments. A higher 
rate of migration has been described in covered stents because of 
their lower degree of fixation to bowel walls. Migration can oc-
cur early and can be related to initial malposition of the stent. To 
avoid migration it is important to center the stent in the stricture 
and always use a longer stent that covers 2 to 4 cm of normal 
colon proximal and distal to the lesion. Manipulation of the stent 
by rectal exams and colonoscopy can cause displacement of 
the stents. Migration is more frequent after chemotherapy, laser 
pretreatment, and dilatation prior to stent insertion, as well as in 
patients with strictures of benign etiology. Migration can lead to 
recurrence of the obstructive symptoms, but in many cases the 
improvement of the stricture after chemoradiation leads to the 
migration and additional intervention may be not required.14,19 In 
most instances, the stent migrates distally and sometimes the stent 
passes out through the anus (Fig. 4). However, the moving distal 
end of the migrated stent can cause severe pain or even perfora-
tion by the continuous irritation of the colorectal wall.2 Migration 
of the stent proximal to the stricture is also possible, these stents 
are usually not removed due to the technical difficulties, restent-
ing the obstruction is usually performed and the migrated stent is 
left in place.
Retrieving migrated stents is usually a very uncomfortable 
and painful procedure especially when significant manipulation 
is required. Care should be taken to avoid perforation or injury of 
the rectal mucosa during stent retrieval. The first step is to iden-
tify the type of migrated stents and the physical characteristics 
of the metal. The use of a plastic sheath through anus as protec-
tion such as a gynecologic speculum has been reported. Migrated 
stents can be retrieved using a variety of techniques. The choices 
for fluoroscopic retrieval are more limited that the endoscopic 
techniques. Reported techniques include using snares to grab the 
ends of the stent, folding the stent after passing a wire through 
the stent lumen that then is snared, using special cups, forceps or 
finger extraction.
Many colorectal SEMS used in Asia and Europe have a re-
trieval systems that allow easy and atraumatic removal. The 
drawstring of the systems allows collapsing the distal end of the 
stent to facilitate retrieval.23 The drawstring can be grabbed with a 
special hook under fluoroscopic guidance or with a forceps under 
endoscopic guidance. In some cases the drawstring is broken or 
embedded in the mucosa and may not be reachable, stent retrieval 
can be performed using the eversion technique where the more 
distal end of the stent is grabbed with the hook and the stent is 
everted and retrieved.28 Another described technique is to grab the 
proximal mesh at the end of the stent and retrieve the stent in an 
expanded form.28 Some stents can become encased by the colonic 
mucosa and may be impossible to remove; excessive manipulation 
may result in mucosal injury, perforation or severe bleeding.27
Reobstruction
Colonic reobstruction is primarily reported in patients with 
colorectal SEMS placed for palliation. The median rate of reob-
struction is 12% (range, 1%–92%). The majority of reobstructions 
result from tumor invasion.20 Rarely stent collapse or stent frac-
ture can lead to reocclusions. Stent obstructions occur from 48 
hours to 480 days after placement and treatments included laser 
therapies to ablate obstructing tissue, restenting, surgery, and 
colonic irrigation.14,17 In most cases restenting provides a defini-
tive solution. Covered stents have a lower incidence of tumor in-
growth, but technical difficulties during deployment due to larger 
delivery systems, and a higher incidence of stent migration, have 
precluded a wider acceptance of this type of stents in the colon. 
Stoma creation may be ultimately required for patients that devel-
op reobstruction when restenting and/or other minimally invasive 
alternative are not possible.
Complications of Gastroduodenal Stenting 
Gastric outlet obstruction (GOO) is a common complication 
A B C D
Fig. 4. (A) Posteroanterior radiograph shows a Wallstent placed in the rectosigmoid (arrow). (B, C) Anteroposterior radiographs taken 2 and 3 days after stent place-
ment shows migration of the stent into the rectum (arrows). (D) Radiograph shows that the stent is no longer present. The stents was defecated. 
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of some advanced malignancies, especially gastric cancer in the 
East, and pancreatic cancer in the West. Placement of SEMS has 
become a widely accepted alternative for the palliation of ob-
structive symptoms in patients that are not considered surgical 
candidates for tumor resection. The overall incidence of complica-
tions of GD stenting varies from 17% to 36% (Table 3).29–33 Most 
randomized studies and meta analysis have demonstrated that GD 
stenting is associated with a decrease in the hospitalization days, 
faster initiation of oral intake and overall lower cost than surgical 
gastrojejunostomy; however, after 60 days, surgery has better oral 
intake rates than SEMS in some recent studies.30 The higher rein-
tervention rates and shorter patency of GD stents than surgery is 
mainly because of stent malfunction due to migration and stents 
occlusion.30,34 Recent recommendations suggest that surgery may 
be a better option for patients where the expected survival is lon-
ger than 2 months, while patients with advanced disease, metas-
tasis, severe malnutrition, concomitant biliary obstruction or poor 
performance status may benefit more from SEMS.35,36 Nonetheless, 
SEMS placement is still considered the treatment of choice over 
surgical palliation in many institutions due to its less invasive na-
ture. 
Procedural Complications
Adequate planning of the procedure and proper patient 
preparation are essential to prevent complications. Review of the 
previous radiological images such as upper digestive series and/or 
CT scans is very important in order to determine the length and 
location of the stenosis, rule out perforation and identify any ad-
ditional sites of distal obstruction. Placement of a proximal stent 
may not relieve the obstruction in patients with multiple sites of 
obstruction; a potential problem in patients with advanced ma-
lignancies and peritoneal carcinomatosis. Early in the experience 
with GD stents, the use of the gastrostomy route was many times 
necessary, as the available stents were too short and too rigid. 
Additional complications related to the gastrostomy access have 
been reported such a leakage of ascites fluid.37 Nowadays the use 
of this route is seldom required. 
Aspiration of gastric contents can be a fatal complication in 
these debilitated patients. The dilated stomachs should be drained 
with a nasogastric tube before the procedure, this will not only 
prevent aspiration, but also facilitates placement of the stent, as 
advancement of the stent delivery system in very dilated stomach 
can be very challenging.38
Minor Complications 
Abdominal pain 
Most patients feel mild abdominal discomfort for a few days 
after GD SEMS placement. The pain disappears spontaneously 
in most patients within 1 to 3 days. Rarely patients may require 
analgesics until they die. The incidence of this complication varies 
from 2% to 8%.39,40 The mechanism of pain is mostly unknown 
but potential reasons for pain include pressure of the stents 
against the tumor, sharp ends of the stent against the intestinal 
mucosa causing penetration/perforation. The presence of severe 
pain requires urgent investigation with CT scan and/or abdominal 
radiographs to rule out perforation. Chronic incapacitating pain 
is caused many times by the malignancy itself. In patients with 
pancreatic cancer with refractory pain, celiac ganglion block by 
radiological or endoscopic techniques can be very effective. 
Low grade fever 
Low grade fever can occur soon after SEMS placement; the 
exact incidence is not well reported. Most of the time fever re-
solves spontaneously within 1 to 2 days. The presence of high 
fevers should prompt an investigation to rule out serious compli-
cations such as perforation, cholangitis or abscess formation.
Stent collapse and incomplete expansion 
The radial force of the stents varies among the different man-
ufacturers. Some tumors have a very hard consistency and the 
stent won’t expand but itself and may require balloon dilatation. 
The incidence of stent collapse seems to be higher with covered 
than with uncovered SEMS (1.9% vs 0.3%). The incidence of in-
complete expansion is 0.9%.33 In some rare cases even after bal-
loon dilatation the stent won’t expand completely and the patient 
may require dietary restrictions to a semi solid diet.41 
Major Complications 
Bleeding
Significant gastrointestinal bleeding requiring blood transfu-
sions or additional intervention is very unusual after placement 
of GD stenting. Most episodes of bleeding are self-limited and 
resolve spontaneously, with a reported incidence of 1% to 6% 
(average 4.1%).33,39,40 Major bleeding has an incidence of 0.8%.33 
Friable tumors can bleed during the instrumentation to place 
the stent. Other potential causes of bleeding include pressure of 
the mesh of the stent over the tumors, sharp ends of some stents 
against the intestinal mucosa, or the pressure of the ends of the 
stents in angulated areas of the duodenum that can create areas 
of ulceration with associated bleeding. Bleeding can present as 
hematemesis or melena. Fatal bleeding is very rare but has been 
reported.41 Management of bleeding includes initial stabilization 
of the blood pressure, correction of any coagulation disorders and 
blood transfusion. An initial upper endoscopy with possible cau-
terization or clipping of the bleeding sites is performed. In refrac-
Table 3 Main Complications after Gastroduodenal Stent Placement
Complication Incidence (%)
Major
    Perforation < 2
    Migration
        Non covered stent 0–6
        Covered stent 20–56
        Partially covered 11
    Stent dysfunction 3–46
    Pancreatitis Rare
    Biliary obstruction 3–6
    Bleeding 1–6
Minor
    Pain 2–8
    Low grade fever < 5
    Stent collapse 0.3–1.9
    Incomplete expansion 0.9
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tory cases, catheter angiography with embolization is performed. 
Surgical intervention is rarely required. Tumoral bleeding can be 
controlled with additional radiotherapy. Massive bleeding related 
to an aorto-enteric fistula has been reported in one case that was 
managed with placement of a stent-graft in the aorta.42
Perforation 
Perforation can be an early or late complication. This compli-
cations is relatively rare (1.2%) but can have devastating conse-
quences.33,43,44 Some perforations are related to technical problems 
with stent deployment and advancement of the delivery system, 
especially in long and tortuous stenosis. Perforations can be 
caused by the guidewire, the stent delivery system or after balloon 
dilatation.33 Procedural related perforations can be detected when 
extravasation of the contrast material is noted and can be man-
aged by placement of a covered stent.11 Potential mechanism of 
late perforation include stent migration, pressure ischemia/necro-
sis by the end of the stents, or penetration of the sharp end of the 
stents (Fig. 5).38–40,45 
In most cases perforations are recognized when patients com-
plain of severe abdominal pain and CT scans show the presence 
of free air. In most patients emergency laparotomy is required to 
close the perforation. Given the poor general condition of many 
of these patients, perforations are associated with high mortal-
ity rates. Some contained perforations may result in localized 
abscesses that be drained surgically or percutaneously. Focal 
perforations can be managed with stent removal and clip place-
ment to seal the perforation or with placement of a covered stent. 
Some contained perforations can result in fistulas to the biliary or 
gastrointestinal system that may be detected incidentally during 
follow-up (Fig. 6).37 
Pancreatitis 
Pancreatitis is a rarely reported after GD stent placement. One 
case of moderate pancreatitis was reported by Kanno et al46 and 
two cases by Maetani et al47 with the use of esophageal stents in 
the GD area. Postulated mechanisms include obstruction of the 
pancreatic duct by the stent, or most likely the axial and radial 
forces exerted by the stent over the pancreas. 
Stent dysfunction 
The exact incidence of stent dysfunction is not really known 
as many terminal patients are too sick to have additional studies. 
The poor oral intake is many times attributed to stent dysfunction, 
but other factors such severe anorexia, motility disorders refrac-
tory to prokinetic medications, and distal obstructions may cause 
the poor food tolerance.40 
Overall recurrent obstruction rates varies from 3% to 46% 
with an average of 19.6%.33,35,39 As palliative chemoradiotherapy 
regimens improve survival, the problem of stent dysfunction be-
comes an even more significant. Stent dysfunction can be related 
to incomplete stent expansion, stent collapse, stent migration, 
stent fracture (Fig. 7) and stent obstruction caused by tumor in-
growth or tumor overgrowth (Fig. 8). 
Tumor ingrowth/overgrowth have been reported in 17.2% of 
patients who receive bare metal stents and 6.9% of those with 
covered stents.41,48 However, the stent migration rates with cov-
ered stents have been very high. Tumor ingrowth has been also a 
problem with the use of some covered stents, as the polyurethane 
or silicone of the membrane covering some stents can disintegrate 
over time due to mechanical damage and/or chemical disintegra-
tion.48 The use of more permanent materials such as polytetrafluo-
roethylene (PTFE) or nylon has reduced this problem.48,49 Jang et 
al48 reported an incidence of tumor overgrowth of 0.8% with the 
use of a dual stent covered with a nylon membrane with tumor 
obstruction occurring later after and more commonly in the duo-
A B C D
Fig. 5. (A) Axial computed tomography (CT) with oral and intravenous contrast shows a contained perforation with free air near the edge of a duodenal stent (curved 
arrow). Note a metallic biliary stent (arrow). (B) Upper endoscopy reveals the perforation caused by the edge of the stent (curved arrow). (C) Upper endoscopy after 
stent removal shows clip placement to seal the perforation. (D) Axial CT scan shows placement of a new stent with successful exclusion of the perforation. 
Fig. 6. Oblique upper gastrointestinal series with oral contrast shows a fistula 
between the duodenum and the jejunum (arrow) after placement of a duode-
nal stent. Patient was asymptomatic. 
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denal region.
Some studies support that the use of chemotherapy after stent 
placement is associated with improved stents patency,31,40 while 
others50 studies show that it does not improve stent patency in 
patients with malignant GOO. It has also been suggested that ag-
gressive tumors such as pancreatic cancers tend to have shorter 
times for stent occlusion that other type of malignancies.51 
In most cases the reobstruction is treated with additional stent 
placement with excellent technical and clinical success rates. The 
occlusion rates after secondary SEMS placement varies from 10% 
to 34%. Complications described after secondary stenting include 
perforation that may be more frequent with overlapping stents 
placed in the curved portions of the duodenum placement, espe-
cially when more rigid stents are used.39,48,52,53
When a patient presents with recurrent obstruction a careful 
evaluation of the overall patient condition and performance status 
is required to decide the best palliation method. Some patients in 
terminal stages may be better managed with supportive therapies, 
while others require reinterventions. In most cases revision of the 
occluded stents is done by endoscopic or radiological methods 
with secondary stent placement. Surgical or laparoscopic gastro-
jejunostomy is also a good alternative in those patients that still 
have a reasonable life expectancy. Recently the use of endoscopic 
ultrasound (EUS)-guided gastrojejunostomy with placement of a 
covered stent has been reported.54 
Stent migration 
The incidence of stent migration of non-covered stent is rela-
tively low varying from 0% to 6% (average 2.2%). The mesh of 
the stent tends to get embedded in the duodenal or gastric mucosa 
preventing migration.33,40,41 
Placement of stents of appropriate length to cover the tumor 
at least 2 cm proximal and distal to the end of the obstruction is 
very important to prevent migration, as shorter and/or overlap-
ping stents can migrate more frequently. When using braided 
stents such as the Wallstent and the Wallflex, the significant 
shortening of these stents needs to be taken into consideration to 
cover the lesion appropriately. 
Migration with covered SEMS is common with frequencies 
of 20% to 56%32,33,43,55 while migration rates for partially covered 
stents are 10.9%.33 Placements of covered stents in the C loop of 
the duodenum and at anastomosis have a greater tendency to mi-
grate.56 Another cause of migration is the use of chemoradiation 
with tumor shrinkage.57
 Various modifications in the designs of the SEMS have been 
A B C
Fig. 7. Patient with malignant gastric outlet obstruction treated with a Wallflex now with recurrent obstruction. (A) Plain film shows fracture of the metallic stent. (B) 
Computed tomography scan shows fractured stent with severe tumor ingrowth (arrow). (C) Upper endoscopy in another patient with fractured stent.
A B
Fig. 8. Upper gastrointestinal series (A) and endoscopy (B) show tumor ingrowth (arrows) of a gastroduodenal uncovered stent, patient was treated with a second 
covered stent. 
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described in order to decrease migration, including stents with an 
hourglass design, partially covered stents, modified large stents 
and dual stents.41,58–60 A recent trial with a “bid cup” stent was 
stopped prematurely due to high migration rates.60 Song et al41 
have described their extensive clinical experience using a dual 
stent where a non-covered stent is placed initially followed by 
placing covered stent inside, with reported migration rates of 2% 
to 4% and excellent patency rates.31 The technique has not gained 
widespread popularity due to its technical complexity of needing 
to place two stents, and the fact that the procedures are done by 
fluoroscopy alone without the use of endoscopy. Recently the use 
of an endoscopic clip seems have shown to be a very successful 
technique in preventing stent migration.61,62 
Migration can be partial or complete, and upwards or down-
wards. In the duodenal area migration is usually downward (Fig. 9), 
while upward migration is possible with stents placed in the antrum 
and pylorus (Fig. 10). Complete distal migration can result in bowel 
obstruction or perforation requiring surgery.38 The stents can also 
pass spontaneously. If a decision is made to observe the migrated 
stent, close observation is needed to detect any signs of perforation 
early. In a study of 70 patients with migrated stents, mainly esoph-
ageal stents and 11 GD stents, forty migrated stents were removed 
with retrieval devices under fluoroscopic guidance, 15 stents exited 
via the rectum, 12 remained in the body without complications and 
3 were surgically removed because they caused complicated intesti-
nal obstructions.56
The techniques to remove the migrated stents vary between 
endoscopic and radiological methods. Many of the current stents 
have a retrieval system to allow collapsing the stent to facilitate 
removal. The migrated stent can be removed from the stomach 
using endoscopic or radiologic methods.38 In terminal patients 
with no recurrent obstruction or pain caused by the migrated 
stent, leaving the stent in the stomach can be a safe alternative.63 
Removing a stent that have migrated distally into the small bowel 
can be very challenging and can be associated with perforation. 
A careful decision needs to be made if leaving the stent alone is 
possible with restenting the obstruction if the patient is symptom-
atic, versus surgical removal or attempt of removal by endoscopic 
means.56 Radiological removal of GD stents has been reported in 
6 patients by Yoon et al28 using a retrieval hook to grab the lasso 
and collapse the stent, grabbing the proximal mesh, or using a 
technique to cause eversion of stent. 
Biliary obstruction 
Patients with malignant GOO can present with biliary obstruc-
tion before the intestinal obstruction present with simultaneous 
biliary and duodenal obstruction, or develop the biliary obstruc-
tion after enteral stenting.29 Prospective studies have shown that 
biliary obstruction occurs in 2% to 6% of patients following a GD 
stent placement for malignant GOO.39 
In patients with GOO, secondary biliary obstruction is most 
common in patients with malignant tumors that involve the duo-
denum, especially pancreatic cancer. Placement of a covered stent 
in a duodenal obstruction may also cause bile duct obstruction by 
mechanical occlusion of the ampulla of Vater. Recent data suggest 
that if the patient has no associated biliary obstruction, develop-
ing secondary biliary obstruction after placement of a covered GD 
stent is not as frequent as initially reported. In one study, none of 
53 patients with covered stents placed over the papilla developed 
biliary obstruction.64 While Kim et al65 reported only one case of 
stent caused biliary obstruction after duodenal covered (n = 27) or 
non covered (n = 35) SEMS placement under fluoroscopic guid-
ance. 
In patients undergoing GD stenting, simultaneous placement 
of a biliary stent without an overt or impending biliary obstruc-
tion, or so called prophylactic biliary stenting, has been a highly 
controversial issue. When the decision is made to stent both bili-
ary and duodenal system using endoscopy, it is recommended to 
stent the biliary system first and then place the duodenal stent 
after, as placing a biliary stent through the mesh of a duodenal 
stent is technically very difficult.66 Simultaneous biliary and 
duodenal stenting has its own challenges and complications. In 
patients with severe stenosis of the duodenum, balloon dilatation 
may be required in order to advance the side-viewing duodeno-
scope, this may result in bleeding, luminal edema and there is a 
risk of duodenal perforation due to the narrow, acute angulation 
in the duodenum.66,67 
When patients with an existing GD stent develop jaundice, 
biliary stenting through the mesh of the stent can be performed 
Fig. 9. Oblique abdominal radiograph shows distal migration of an overlap-
ping duodenal stent (arrow). 
Fig. 10. Upper endoscopy shows forceps grabbing proximal end of a gastro-
duodenal stent that migrated into the stomach. 
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endoscopically but it is very difficult. Techniques described in-
clude balloon dilatation of the mesh, cutting wires or burning the 
wires with argon plasma coagulation.68,69 Percutaneous drainage 
and stenting have a higher technical success. 
Recently EUS-guided biliary drainage has been performed 
successfully through the duodenum or the mesh of an existing 
duodenal stent. Complications of EUS-guided procedures includ-
ing bile leaks, peritonitis, pneumoperitoneum, bleeding, and chol-
angitis, can occur in up to 15% of patients.70
In conclusion, treating malignant colonic and GOO obstruc-
tion with SEMS is a safe, feasible, and effective procedure for pal-
liation of obstructive symptoms, with important clinical benefits 
and significant improvement in quality of life for the patients. 
However, SEMS placement can be associated with some signifi-
cant early and late complications that many times require reinter-
ventions. While the search for the ideal SEMS continues, judicious 
use of SEMS in the appropriate clinical situation is of paramount 
importance. Collaborative and prospective randomized studies are 
needed to establish the best palliation method in every patient. 
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